12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Adcetris brentuximab vedotin: SPA received

Seattle Genetics disclosed in its 3Q12 earnings that it received an SPA from FDA for a planned Phase III trial to evaluate Adcetris for first-line treatment of mature T cell lymphomas, including systemic anaplastic large cell lymphoma (ALCL). The biotech expects to start the trial by late 2012 or early 2013. In August 2011, FDA granted accelerated approval to Adcetris to treat Hodgkin's...

Read the full 295 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >